• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride: A Comprehensive Overview

1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride (CAS No. 1431963-24-4) is a novel compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications. In this article, we will delve into the chemical properties, synthesis methods, biological activities, and recent research advancements related to this compound.

Chemical Structure and Properties

1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride is a derivative of pyrazole, a five-membered heterocyclic compound with two nitrogen atoms. The presence of the difluoroethyl group and the methanamine moiety imparts distinct chemical properties to this compound. The difluoroethyl group enhances the lipophilicity and metabolic stability of the molecule, while the methanamine functionality provides a reactive site for further functionalization and conjugation with other biomolecules.

The dihydrochloride salt form of this compound ensures its solubility in aqueous media, making it suitable for various biological assays and pharmaceutical formulations. The molecular formula of 1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride is C₉H₁₀F₂N₃·2HCl, with a molecular weight of approximately 258.14 g/mol.

Synthesis Methods

The synthesis of 1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride involves several well-established organic reactions. One common approach is to start with the reaction of 3-bromopyrazole with 2,2-difluoroethyl bromide to form the corresponding difluoroalkylated pyrazole intermediate. This intermediate is then subjected to a reductive amination reaction using formaldehyde and ammonia to introduce the methanamine group. Finally, the free amine is converted to the dihydrochloride salt by treatment with hydrochloric acid.

This synthetic route is highly efficient and scalable, making it suitable for both laboratory-scale synthesis and industrial production. Recent advancements in catalytic methods have further optimized this process, reducing reaction times and improving yields.

Biological Activities and Therapeutic Potential

1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride has been extensively studied for its biological activities and potential therapeutic applications. One of its key properties is its ability to modulate various biological targets, including enzymes, receptors, and ion channels.

In particular, this compound has shown promising activity as an inhibitor of specific enzymes involved in metabolic pathways. For example, recent studies have demonstrated that it effectively inhibits the activity of certain kinases and proteases, which are implicated in various diseases such as cancer and inflammatory disorders. This makes it a potential lead compound for the development of novel therapeutic agents.

Beyond its enzymatic inhibition properties, 1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride has also been investigated for its anti-inflammatory effects. Preclinical studies have shown that it can reduce inflammation by modulating the expression of pro-inflammatory cytokines and chemokines. These findings suggest that it may have therapeutic potential in treating inflammatory conditions such as arthritis and asthma.

Clinical Trials and Future Directions

The promising preclinical results of 1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride have led to its advancement into early-stage clinical trials. These trials are aimed at evaluating the safety, tolerability, and pharmacokinetic profile of the compound in human subjects. Initial data from these trials have been encouraging, with no significant adverse effects reported at therapeutic doses.

Ongoing research is focused on optimizing the formulation and delivery methods of this compound to enhance its bioavailability and therapeutic efficacy. Additionally, efforts are being made to identify synergistic combinations with other drugs to broaden its therapeutic applications.

Conclusion

1-(2,2-difluoroethyl)-1H-pyrazol-3-ylmethanamine dihydrochloride (CAS No. 1431963-24-4) represents a promising candidate in the development of novel therapeutics for various diseases. Its unique chemical structure confers favorable properties such as enhanced lipophilicity and metabolic stability. Extensive preclinical studies have demonstrated its potential as an inhibitor of key enzymes involved in disease pathways and as an anti-inflammatory agent.

Ongoing clinical trials are expected to provide further insights into its safety and efficacy in human subjects. As research continues to advance, this compound holds significant promise for addressing unmet medical needs and improving patient outcomes in various therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)